Commercialization: Page 4
-
iStock via Getty Images
How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues
Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.
By Alexandra Pecci • Feb. 26, 2024 -
ismagilov via Getty Images
BioMarin preaches patience amid slow sales for hemophilia gene therapy
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
By Ben Fidler • Feb. 23, 2024 -
Courtesy of Biogen
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
By Michael Gibney • Feb. 15, 2024 -
Stock via Getty Images
3 questions hanging over the Novo-Catalent deal
As backlash builds for the recently announced matchup, critical questions remain over its impact.
By Kelly Bilodeau • Feb. 13, 2024 -
iStock via Getty Images
These 4 drugs had tons of promise — and they flopped. What happened?
No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.
By Alexandra Pecci • Feb. 13, 2024 -
Stock via Getty Images
Could Novo, Lilly become first trillion-dollar healthcare companies?
Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.
By Meagan Parrish • Feb. 2, 2024 -
Stock via Getty Images
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
Stock via Getty Images
What are pharma’s next blockbusters?
In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.
By Kelly Bilodeau • Dec. 20, 2023 -
Permission granted by Adam Lenkowsky
Q&ABristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
By Michael Gibney • Dec. 12, 2023 -
Justin Sullivan via Getty Images
Q&A // First 90 DaysPatients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
By Alexandra Pecci • Dec. 11, 2023 -
Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP
Deep DiveWhat if a CRISPR cure isn’t such an easy choice?
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023 -
Carsten Koall/Getty Images via Getty Images
What’s next for COVID dark horse Novavax?
Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?
By Kelly Bilodeau • Oct. 30, 2023 -
Permission granted by Sumitomo Pharma America
Q&A // Red Jacket winners 2023Red Jacket: Adele Gulfo, a commercialization guru
With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.
By Karissa Waddick • Oct. 27, 2023 -
Stock via Getty Images
3 marketing tips for biotechs emerging from stealth
In a crowded biotech market, here’s how your company can stand out to investors.
By Karissa Waddick • Oct. 6, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Brand and commercialization pros
Leaders decoding the complex language of drug development to push treatments past the finish line and into patients’ hands.
By Karissa Waddick • Oct. 4, 2023 -
Tinnakorn Jorruang via Getty Images
How pharma marketers can reclaim the drug pricing narrative
As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.
By Karissa Waddick • Sept. 28, 2023 -
Permission granted by Phil Inc
Sponsored by Phil IncOptimizing your hub services program with a gross-to-net lens
In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.
Sept. 25, 2023 -
iStock via Getty Images
Q&AAs the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
By Michael Gibney • Sept. 21, 2023 -
iStock via Getty Images
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
saengsuriya13 via Getty Images
Q&AIn the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
By Michael Gibney • Sept. 14, 2023 -
Courtesy of Sanofi
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
By Karissa Waddick • Sept. 14, 2023 -
Permission granted by CSL Seqirus
Finding the right flu vaccine is hard. Getting people to take it is harder.
Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.
By Michael Gibney • Aug. 30, 2023 -
Stock via Getty Images
Are weight loss drugs a win for the global economy?
As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we’re examining wider implications for the weight loss market.
By Karissa Waddick • Aug. 28, 2023 -
Steve Ruark/AP
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Arsen Volkov via Getty Images
Behind Flagship Pioneering’s triumphs and tribulations
From the rise of Moderna to the fall of Kaleido, here’s a look at the VC fund’s biggest successes and failures to date.
By Karissa Waddick • Aug. 18, 2023
Previous
